Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

CorMedix (CRMD) Non Operating Income (2016 - 2025)

CorMedix (CRMD) has disclosed Non Operating Income for 12 consecutive years, with -$2.7 million as the latest value for Q4 2025.

  • Quarterly Non Operating Income fell 9.55% to -$2.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$124999.0 through Dec 2025, down 319.29% year-over-year, with the annual reading at -$125000.0 for FY2025, 319.3% down from the prior year.
  • Non Operating Income hit -$2.7 million in Q4 2025 for CorMedix, down from $1.2 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $1.2 million in Q3 2025 to a low of -$2.7 million in Q4 2025.
  • Historically, Non Operating Income has averaged $102614.1 across 5 years, with a median of $180277.0 in 2022.
  • Biggest five-year swings in Non Operating Income: tumbled 379.88% in 2021 and later soared 24647.35% in 2023.
  • Year by year, Non Operating Income stood at -$11066.0 in 2021, then surged by 1729.11% to $180277.0 in 2022, then soared by 301.01% to $722929.0 in 2023, then tumbled by 438.37% to -$2.4 million in 2024, then fell by 9.55% to -$2.7 million in 2025.
  • Business Quant data shows Non Operating Income for CRMD at -$2.7 million in Q4 2025, $1.2 million in Q3 2025, and $805983.0 in Q2 2025.